髓质囊性肾病 中国就医指南

Medullary Cystic Kidney Disease (MCKD) is a rare, inherited form of chronic tubulointerstitial nephropathy characterized by progressive renal tubular atrophy, interstitial fibrosis, and the development of small, non-obstructive cysts primarily in the renal medulla and corticomedullary junction. Historically grouped with familial juvenile hyperuricemic nephropathy (FJHN) and uromodulin-associated kidney disease (UAKD), MCKD is now recognized as part of the broader spectrum of autosomal dominant tubulointerstitial kidney diseases (ADTKD), most commonly caused by pathogenic variants in the *UMOD* (uromodulin), *REN* (renin), *HNF1B* (hepatocyte nuclear factor 1-beta), or *MUC1* (mucin-1) genes. The hallmark pathogenic mechanism involves misfolding and intracellular retention of mutant uromodulin protein in thick ascending limb cells, triggering endoplasmic reticulum stress, inflammation, and progressive tubular dysfunction—leading to impaired urine concentration, hyperuricemia, gout, and gradual decline in glomerular filtration rate (GFR). Unlike polycystic kidney disease, MCKD cysts are few, small, and not diagnostic on imaging alone; diagnosis relies on genetic testing, family history, and exclusion of secondary causes. Epidemiologically, MCKD is exceptionally rare, with an estimated prevalence of fewer than 1 in 1,000,000 individuals worldwide; it accounts for <1% of cases requiring renal replacement therapy in adults with hereditary kidney disease. Most patients present between ages 30–60 with nonspecific symptoms including polyuria, nocturia, mild hypertension, recurrent gout, or incidental detection of elevated serum creatinine or uric acid. Risk factors include autosomal dominant inheritance (50% transmission risk to offspring), specific founder mutations (e.g., *UMOD* p.Cys127Trp in European families), and environmental modifiers such as dehydration, NSAID use, or chronic volume depletion that accelerate tubular injury. Importantly, MCKD does not typically cause extrarenal manifestations, but its insidious progression often leads to end-stage kidney disease (ESKD) by the sixth or seventh decade—necessitating dialysis or transplantation. Quality of life is significantly impacted: patients face lifelong monitoring, dietary restrictions (low-purine, sodium- and protein-modified diets), frequent gout flares, fatigue, anxiety about disease progression and familial transmission, and psychosocial burden related to genetic counseling and reproductive decision-making. While kidney transplantation offers excellent long-term outcomes (with no recurrence of disease in the allograft), pre-transplant management focuses on conservative nephroprotection—optimizing blood pressure, avoiding nephrotoxins, managing hyperuricemia with uricosurics (e.g., lesinurad) or xanthine oxidase inhibitors (e.g., febuxostat), and addressing electrolyte imbalances. Early genetic diagnosis enables proactive surveillance and family screening, improving clinical trajectory and reducing diagnostic odyssey.

# 髓质囊性肾病治疗方案与费用明细（肾内科）

一、非手术/保守治疗

适用于早期（eGFR ≥60 mL/min/1.73m²）、无显著蛋白尿及高血压者。

• •基础管理：低盐低蛋白饮食+定期随访（每3–6个月）：200–500元/次（含尿常规、血肌酐、电解质、肾脏超声）
• •血压控制（ACEI/ARB类）：如厄贝沙坦片（国产）：30–120元/月；进口制剂：200–450元/月
• •并发症干预：高尿酸血症（别嘌醇）：20–80元/月；贫血（促红素注射液）：800–2500元/月（依剂量及疗程）

二、手术/介入治疗

本病无根治性手术，终末期需肾脏替代治疗：

• •血液透析（维持性）：350–550元/次（公立三甲医院），年均约12–18万元（含透析费、抗凝药、铁剂等）
• •腹膜透析：置管术8000–12,000元；后续耗材（透析液+导管护理）：4500–6500元/月，年均约5.4–7.8万元
• •肾移植：术前评估（基因检测+HLA配型+心肺功能）：1.2–2.5万元；手术及住院（含免疫抑制剂首月）：25–35万元（医保报销后自付约8–15万元）

三、晚期/并发症强化方案

eGFR <15 mL/min或合并严重肾性骨病、心衰者：

• •多学科联合管理（肾内+营养+心血管）：1500–3000元/次门诊（含骨代谢指标、心脏超声、营养评估）
• •肾性贫血难治性者加用罗沙司他：2800–3600元/月

方案快速选择指南

• •预算有限/早期患者：优选保守治疗+腹膜透析过渡（年支出≤8万元）
• •中高预算/年轻患者：优先评估肾移植（长期成本效益最优）
• •晚期合并多系统衰竭：血液透析联合MDT管理，保障生存质量